Intelligent Heart Failure ​Monitoring Platform

HemoCath-Guided Heart Failure Management  Reducing Hospital Length of Stay and Rehospitalization*

​

• ​Monitoring pulmonary artery pressure (PAP) and central venous pressure (CVP) for inpatients and outpatients
  
  
• ​Substantially less invasive, more accurate and easier-to-use compared to current medical devices
  
  
• ​Communicating with patients’ mobile phone and a secure cloud
  
  
• ​Remote patient monitoring services (AI, SaaS)
  ​
• ​Reducing hospital length of stay and rehospitalization for patients with heart failure*

HemoCath Ltd is an early-stage Canadian/Irish/US company that has developed over the past 7 years the HemoCath Intelligent Heart Failure Monitoring Platform. HemoCath proprietary medical devices and remote patient monitoring platform address large unmet clinical needs for PAP-guided diagnostic, treatment and monitoring of patients with heart failure. HemoCath-guided heart failure management will soon become the standard of care –  reducing hospital length of stay and rehospitalization for heart failure patients.*

*  CardioMEMS and CHAMPION clinical studies have shown that PAP-guided heart failure management reduces hospital length of stay by 42% (1.6 days) and 30-day readmissions by 58% compared to the standard of care for patients with heart failure.  See: PubMed.gov and Circ Heart Fail.

Problems Resolved

The two most important metrics for the treatment of heart failure are the pulmonary artery pressure (PAP) and the central venous pressure (CVP). Unfortunately, these two metrics are not easily available today. So, cardiologists use several indirect methods that are LATE and IMPRECISE (e.g. Edema, JVP, Lung sounds, BUN, Cr, BNP, Echo, X-ray). Or, they use medical devices that are TOO INVASIVE and RISKY (e.g. today’s PA catheters, CardioMEMS). Leading to suboptimal medication dosing, suboptimal treatment, longer hospital stay and 30-day rehospitalization.